Do you remember the anticipation around renal denervation? And then the ACC.14 presentation of the SYMPLICITY HTN-3 results, where the excitement about a new way to treat resistant hypertension seemed to crash?
It’s becoming evident that the Stark law is frustrating the move from volume to value. Experts expect changes that could allow health systems and practices to deploy better coordinated, team-based care and advanced alternative payment models.
Patients with heart failure with preserved ejection fraction (HFpEF), who face a high mortality risk and do not respond to conventional therapies, are changing the way clinicians think about heart failure.